The reports have been updated with the most recent Ukraine-Russia War impact on market growth for all 27+ industries. The reports also provide possible solutions and opportunities for surviving this crisis.

Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies!

The oral biologics & biosimilar drugs market is forecasted to achieve exponential growth in the coming few years with a forecast CAGR (compound annual growth rate) of more than 20%, as per The Business Research Company’s market report!

Read More On The Oral Biologics & Biosimilar Drugs Market Report 2022 – https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

The Oral Biologics & Biosimilar Drugs Market Size In 2022 And Forecast

The global oral biologics & biosimilar drugs market is expected to grow from $4.06 billion in 2021 to $4.91 billion in 2022 at a compound annual growth rate (CAGR) of 21%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The oral biologics market is expected to reach $10.41 billion in 2026 at a CAGR of 20.7%.

The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer.

Request for A Sample Of The Global Oral Biologics & Biosimilar Drugs Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

Rise In The Prevalence Of Chronic Diseases Is Driving The Growth Of The Oral Biologics & Biosimilar Drugs Market

According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the oral biologics and biosimilar market.

Competitive Landscape And The Regional Analysis Of The Oral Biologics & Biosimilar Drugs Market

Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline Plc., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and Roche.

Additionally, as per TBRC’s research – North America was the largest region in the oral biologics & biosimilar drugs market in 2021 holding the largest market share and Middle East is expected to be the fastest-growing region in the forecast period.

The Oral Biologics & Biosimilar Drugs Global Market Report 2022  covers regional data on key drivers, opportunities, and strategies for the seven major regions of the world that are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The report includes market size and forecast market shares for all the regions and countries with respect to the major players of the oral biologics & biosimilar drugs market.

Creating New Biosimilar Insulin – A Key Trend In The Oral Biologics & Biosimilar Drugs Market

The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers.

Oral Biologics & Biosimilar Drugs Market Segmentation By The Business Research Company

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors

2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others

3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Here Are Some Reports Related To The Oral Biologics & Biosimilar Drugs Market –

Biologics Global Market Report 2022

Cancer Biologics Global Market Report 2022

Pharmaceuticals Global Market Report 2022

Get In Touch With Us – Call us at:

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Found this article helpful? Share it on: